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OBJECTIVES: To examine the association between kid-
ney function and all-cause mortality in octogenarians.
DESIGN: Retrospective analysis of prospectively collected
data.
SETTING: Community.
PARTICIPANTS: Serum creatinine and cystatin C were
measured in 1,053 Cardiovascular Health Study (CHS) All
Stars participants.
MEASUREMENTS: Estimated glomerular ﬁltration rate
(eGFR) was determined using the Chronic Kidney Disease
Epidemiology Collaboration creatinine (eGFRCR) and
cystatin C one-variable (eGFRCYS) equations. The associa-
tion between quintiles of kidney function and all-cause
mortality was analyzed using unadjusted and adjusted Cox
proportional hazards models.
RESULTS: Mean age of the participants was 85, 64%
were female, 66% had hypertension, 14% had diabetes
mellitus, and 39% had prevalent cardiovascular disease.
There were 154 deaths over a median follow-up of
2.6 years. The association between eGFRCR and all-cause
mortality was U-shaped. In comparison with the reference
quintile (64–75 mL/min per 1.73 m
2), the highest
(75 mL/min per 1.73 m
2) and lowest (43 mL/min
per 1.73 m
2) quintiles of eGFRCR were independently
associated with mortality (hazard ratio (HR) = 2.49, 95%
conﬁdence interval (CI) = 1.36–4.55; HR = 2.28, 95%
CI = 1.26–4.10, respectively). The association between
eGFRCYS and all-cause mortality was linear in those with
eGFRCYS of less than 60 mL/min per 1.73 m
2, and in the
multivariate analyses, the lowest quintile of eGFRCYS
(<52 mL/min per 1.73 m
2) was signiﬁcantly associated
with mortality (HR = 2.04, 95% CI = 1.12–3.71)
compared with the highest quintile (>0.88 mL/min per
1.73 m
2).
CONCLUSION: Moderate reduction in kidney function is
a risk factor for all-cause mortality in octogenarians. The
association between eGFRCR and all-cause mortality dif-
fered from that observed with eGFRCYS; the relationship
was U-shaped for eGFRCR, whereas the risk was primarily
present in the lowest quintile for eGFRCYS. J Am Geriatr
Soc 60:1201–1207, 2012.
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T
here is a high prevalence of chronic kidney disease
(CKD) in elderly adults,
1–3 although there continues
to be controversy regarding the importance of low glomer-
ular ﬁltration rate (GFR) in the absence of other markers
of kidney disease in this population.
4 Several studies have
noted an attenuation of the prognostic importance of
kidney function with advancing age,
5–7 and the data in
octogenarians are particularly sparse.
8 In a cross-sectional
analysis of octogenarians in the Cardiovascular Health
Study (CHS) All Stars cohort, it was found that CKD was
associated with prevalent cardiovascular disease (CVD),
but whether this translates into longitudinal outcomes
remains unknown.
9 Examining the relationship between
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help clinicians understand the implications of CKD in this
growing subgroup of the population.
Use of serum creatinine–based estimating equations
may be particularly limited as a measure of kidney function
in elderly adults, among whom there is low muscle mass.
Cystatin C is a ﬁltration marker that muscle mass inﬂuences
less than it does creatinine
10,11 and thus may have a particu-
lar advantage in elderly adults. Previous studies from the
CHS cohort have shown that cystatin C is a stronger predic-
tor of adverse outcomes than creatinine or GFR estimated
using creatinine-based equations.
12–14 It remains unclear
whether there are similar associations in octogenarians.
Whether reduction in kidney function was associated
with mortality in the oldest old was evaluated. To do so,
the association between kidney function, using creatinine
and cystatin C-based GFR estimated equations, and all-
cause and CVD mortality in octogenarian CHS All Stars
participants was examined.
METHODS
Study Population
Cardiovascular Health Study All Stars, an ancillary study
of CHS, was undertaken to identify factors associated with
successful aging. Sampling and recruitment procedures for
CHS and CHS All Stars have been described in detail else-
where.
15,16 Brieﬂy, CHS was a longitudinal study of com-
munity-dwelling adults aged 65 and older designed to
determine the risk factors, consequences, and natural his-
tory of CVD in older adults. Participants were recruited
from Medicare eligibility lists in four U.S. communities
(Forsyth County, NC; Sacramento County, CA; Washing-
ton County, MD; and Pittsburgh, PA). An initial 5,201
participants were recruited between 1989 and 1990, and
an additional 687 black participants were added to the
study between 1992 and 1993.
During the seventeenth year of follow-up (April 2005–
May 2006), the CHS cohort was re-recruited for the CHS
All Stars Study.
16 Of the 2,281 participants still alive,
1,677 (73.5%) participated in the CHS All Stars Study,
and 265 (11.6%) participated in the CHS telephone fol-
low-up. Of the 1,100 CHS All Stars participants in whom
laboratory data were obtained, creatinine and cystatin C
were measured in 1,053.
Assessment of Kidney Function
All assays were performed at the CHS Core Laboratory in
May and June 2008 on serum stored at 70°C. Serum cre-
atinine, measured using a colorimetric method (Ektachem
700, Eastman Kodak, Rochester, NY) was calibrated to
isotope dilution mass spectrometry, and the intra-assay
coefﬁcient of variation was 1.9%. Cystatin C was mea-
sured using a BN II nephelometer (N Latex cystatin C,
Dade Behring, Munich, Germany) using a particle-
enhanced immunonepholometric assay, and the intra-assay
coefﬁcient of variation for cystatin C ranged from 2.0% to
2.8%. Estimated glomerular ﬁltration rate (eGFR) was
determined using the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation because it is
thought to be more accurate and less biased than the Mod-
iﬁcation of Diet in Renal Disease (MDRD) equation at
higher levels of GFR.
eGFRCR = 141 9 minimum (Scr/j,1 )
a 9 maximum
(Scr/j,1 )
1.209 9 0.993
age 9 1.018 [if female] 9 1.159 [if
black], where Scr is serum creatinine, j is 0.7 for women
and 0.9 for men, a is 0.329 for women and 0.411 for
men, and eGFRCR is expressed in mL/min per 1.73 m
2.
17
Glomerular ﬁltration rate was estimated from cystatin
C using the CKD-EPI equation, with eGFRCYS =
76.7 9 CysC
1.19, GFR expressed as mL/min per 1.73 m
2
of body surface area, and CysC is serum cystatin C
expressed in mg/L.
18
Study Outcome
The primary outcome was all-cause mortality. Information
regarding death after the CHS All Stars visit was ascertained
by review of obituaries, telephone follow-up, and proxy
contact and was available through June 2008. The second-
ary outcome was death from CVD, deﬁned as death caused
by atherosclerotic coronary heart disease, cerebrovascular
disease, other atherosclerotic disease, or other CVD in par-
ticipants with and without prevalent CVD. A committee
adjudicated all events, as previously described.
19
Covariates
Covariates that may confound the association between
poor kidney function and mortality were chosen for multi-
variate analyses. These included demographic variables
(age, sex, and race), cardiovascular risk factors (body mass
index (kg/m
2), hypertension (blood pressure  140/
90 mmHg or antihypertensive treatment)), diabetes mel-
litus (use of insulin or oral hypoglycemic agent or fasting
glucose value 126 mg/dL), smoking status (current smo-
ker, former smoker, never smoked), systolic blood pres-
sure, diastolic blood pressure, low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), clinical CVD (composite of history of coronary
heart disease (angina pectoris, myocardial infarction,
angioplasty, coronary bypass surgery) or (stroke at the
time of initiation of CHS All Stars or heart failure)), and a
novel cardiovascular risk factor (C-reactive protein).
Statistical Analyses
Continuous data are presented as means ± standard devia-
tions and categorical variables as proportions. Analysis of
variance and Pearson Chi-square tests with trend P-values
were used for comparison of quintiles of eGFRCYS for con-
tinuous and categorical variables, respectively. Data for
C-reactive protein are presented as medians and interquar-
tile ranges because its distribution was skewed, and the
Kruskal–Wallis test was used to compare differences
between quintiles of eGFRCYS. Pearson correlation was
used to assess correlation between eGFRCR and eGFRCYS.
Age-, sex-, and race-adjusted splines of eGFRCR and
eGFRCYS were plotted to evaluate the functional form of
their relationship with all-cause mortality. The 2.5% of
the extremes were excluded to remove inﬂuence from the
extremes. Mortality rates per 100 person-years according
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proportional hazards models were used to assess associa-
tions between kidney disease and all-cause mortality in
unadjusted and adjusted models. Covariates were selected
for the analyses based on their biologically plausible
potential to act as confounders and entered into the models
in stages: Model 1, unadjusted; Model 2, demographic fac-
tors (age, sex, and race); Model 3, demographic and cardio-
vascular risk factors and disease. Separate models were
constructed for eGFRCR and eGFRCYS quintiles, and the
same covariates were entered into the models. Taking the
spline into account, for eGFRCYS analyses, the ﬁrst quintile
(>88 mL/min per 1.73 m
2) was used as the reference group,
whereas for eGFRCR, the second-highest quintile (64–
75 mL/min per 1.73 m
2) was used as the reference group.
The association between kidney function and CVD
mortality was examined using the same models. Because of
the small number of CVD deaths in the highest eGFRCYS
quintile (n = 2), the ﬁrst and second quintiles of eGFRCYS
were combined into one group, leading to the following sub-
groups: eGFRCYS 75 mL/min per 1.73 m
2 or greater (refer-
ence group), 65 to 74 mL/min per 1.73 m
2, 52 to 64 mL/
min per 1.73 m
2, and less than 52 mL/min per 1.73 m
2.
Sensitivity Analyses
Two sensitivity analyses were performed to assess the con-
sistency of the results. Most prior studies have used the
one-variable cystatin C equation to estimate GFR,
12,20 but
in a pooled study of individuals with established CKD
with mean age of 52, the cystatin C demographic equation
had slightly higher accuracy and precision and lower bias
than the cystatin C one-variable equation.
18 Therefore, the
analyses were repeated using the cystatin C demographic
equation where eGFRCYS demo = 127.7 9 CysC
1.17 9
age
0.13 9 1.06 (if black) 9 0.91 (if female) where GFR is
expressed as mL/min per 1.73 m
2 of body surface area,
and CysC is serum cystatin C expressed in mg/L.
18 Taking
the spline into account, for eGFRCYS demo analyses, the
ﬁrst quintile (>78 mL/min per 1.73 m
2) was used as the
reference group.
Second, because frailty may be an important confound-
ing variable, additional analyses were performed adjusting
for the presence of frailty. The presence of frailty has previ-
ously been deﬁned as three of the following ﬁve characteris-
tics: recent weight loss, self-reported exhaustion, weakness,
slow walking speed, and low physical activity.
21 Informa-
tion on physical activity was not collected in CHS All Stars,
so frailty was deﬁned according to the presence of three of
the following: unintentional weight loss, exhaustion, weak-
ness, and walking slowness based on gait speed.
Analyses were performed using S-Plus (release 8.0,
Insightful, Inc., Seattle, WA) and SPSS (version 16.0.2,
SPSS, Inc., Chicago, IL). Two-tailed P < .05 was consid-
ered to be statistically signiﬁcant.
RESULTS
Characteristics of Study Participants
One thousand ﬁfty-three CHS All Stars participants were
included in the analyses. Participants who were alive but
did not have laboratory data available were more likely to
be female and older and to have a higher prevalence of
myocardial infarction and stroke than those included in
the analyses.
The clinical characteristics of the study population are
shown in Table 1 according to eGFRCYS quintile. The
average age of the participants was 85, 64% were female,
86% were white, 67% had hypertension, 18% had diabe-
tes mellitus, 35% had prevalent CVD, and 14% had heart
failure. Mean eGFRCr and eGFRCYS were 59 and 70 mL/
min per 1.73 m
2, respectively.
Participants in the lowest eGFRCYS quintiles were more
likely to be older, male, and not black than those in the
highest eGFRCYS quintiles. Nearly all of the comorbid con-
ditions assessed were more prevalent in those with lower
eGFRCYS. Also, participants in the lowest eGFRCYS quintiles
had higher levels of C-reactive protein and lower levels of
HDL-C and LDL-C. The prevalence of diabetes mellitus did
not vary signiﬁcantly between quintiles of eGFRCYS.
Association Between Kidney Function and Mortality
All-Cause Mortality
During a median follow-up of 2.6 years, there were 154
deaths, of which 64 were due to CVD. Quintiles of
eGFRCR had a U-shaped association with mortality. The
second, third, and fourth quintiles of eGFRCYS had slightly
higher mortality than the ﬁrst quintile, and the lowest
quintile had a three times the mortality (Figure 1).
The age-, sex-, and race-adjusted splines for eGFRCR
revealed a more-pronounced U-shaped relationship with all-
cause mortality (Figure 2). In contrast, the adjusted splines
for eGFRCYS revealed a linear relationship with mortality for
participants with eGFR less than 60 mL/min per 1.73 m
2.
The U-shaped association with eGFRCR persisted in
the multivariate analyses, with participants in the highest
(HR = 2.49, 95% CI = 1.36–4.55) and lowest quintiles
(HR = 2.28, 95% CI = 1.26–4.10) having signiﬁcantly
greater risk of mortality than those in the second-highest
quintile (64–75 mL/min per 1.73 m
2) (Table 2). In contrast,
the lowest eGFRCYS quintile was signiﬁcantly more associ-
ated with death than the highest quintile (HR = 2.04, 95%
CI = 1.12–3.71), with the second, third, and fourth quintiles
of eGFRCYS having similar mortality rates and not being
signiﬁcantly different from the reference group.
Cardiovascular Mortality
In multivariable analysis, the U-shaped association
between eGFRCR quintile and CVD mortality persisted,
although none of the differences between eGFRCR quintiles
reached statistical signiﬁcance (Table 3). In contrast, the
lowest subgroup of eGFRCYS (<52 mL/min per 1.73 m
2)
was signiﬁcantly more associated with CVD death than
the highest subgroup (HR = 1.66, 95% CI = 1.06–2.60).
Sensitivity Analyses
When the analyses were repeated using quintiles of
eGFRCYS demo, results were similar to those with eGFRCYS,
with only the lowest eGFRCYS demo quintile being signiﬁ-
cantly more associated with all-cause (HR = 2.01, 95%
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CI = 1.45–9.28) than the highest quintile.
One hundred seven (10%) CHS All Stars participants
met the deﬁnition of frailty. Similar results were obtained
when adjusted for frailty, with the relationship being
U-shaped for eGFRCR, whereas for eGFRCYS, the risk was
primarily present in the lowest quintile. That is, the
highest (HR = 2.43, 95% CI = 1.33–4.44) and lowest
(HR = 2.19, 95% CI = 1.21–3.95) quintiles of eGFRCR
were independently associated more with all-cause mortal-
ity than the reference quintile (64–75 mL/min per
1.73 m
2), and in contrast, only the lowest eGFRCYS quin-
tile was signiﬁcantly associated more with death than the
highest quintile (HR = 1.88, 95% CI = 1.03–3.43).
DISCUSSION
Impaired kidney function assessed using eGFRCR or
eGFRCYS was a signiﬁcant risk factor for all-cause mortal-
ity in this community-based cohort of octogenarians.
The association between eGFRCR and all-cause mor-
tality differed from that observed with eGFRCYS, for which
the relationship was U-shaped for eGFRCR, whereas for
cystatin C, the risk was primarily in the lowest quintile.
Although a similar relationship was noted with CVD mor-
tality, eGFRCR was not associated with CVD mortality,
and only the lowest eGFRCYS subgroup had a greater risk
of CVD mortality.
Whereas the association between impaired kidney
function and outcomes has been clearly described in mid-
dle-aged and elderly adults,
22–24 few studies have evalu-
ated whether impaired kidney function is associated with
mortality in octogenarians
8 and whether any thresholds
regarding this association exist. In the National Cohort of
Veterans Study that compared mortality risk associated
with CKD across all ages, the relative risk for death asso-
ciated with each level of kidney function decreased mark-
edly with age, and creatinine-based eGFR of 50 to 59 mL/
min per 1.73 m
2 was not associated with a greater risk of
death than in the reference group (eGFR  60 mL/min
Table 1. Baseline Characteristics According to Quintile of Cystatin C Estimated Glomerular Filtration Rate
(eGFR)
Characteristic
All,
N = 1,053
Quintile 1
(>88 mL/min
per 1.73 m
2),
n = 195
Quintile 2
(75–88 mL/min
per 1.73 m
2),
n = 213
Quintile 3
(65–74 mL/min
per 1.73 m
2),
n = 224
Quintile 4
(52–64 mL/min
per 1.73 m
2),
n = 216
Quintile 5
(<52 mL/min
per 1.73 m
2),
n = 105 P-value
Age, mean ± SD 85 (4) 84 (4) 85 (4) 86 (3) 85 (3) 86 (4) <.001
Male, n (%) 381 (36) 61 (31) 64 (30) 83 (37) 83 (38) 90 (44) .002
Black, n (%) 170 (16) 47 (24) 35 (16) 30 (13) 34 (16) 24 (12) .002
Body mass index, kg/m
2,
mean ± SD
26.8 (4.7) 26.3 (4.4) 26.5 (4.2) 26.8 (4.8) 27.2 (4.9) 27.3 (5.0) .01
Smoking, n (%) .43
Never 536 (51) 109 (56) 104 (49) 111 (50) 112 (52) 100 (49)
Former 481 (46) 80 (41) 101 (47) 102 (46) 101 (47) 97 (47)
Current 36 (3) 6 (3) 8 (4) 11 (5) 3 (1) 8 (4)
Prevalent heart failure, n (%) 151 (14) 14 (7) 22 (10) 26 (12) 32 (15) 57 (28) <.001
Prevalent cardiovascular
disease, n (%)
363 (35) 53 (27) 64 (30) 63 (28) 81 (38) 102 (50) <.001
Diabetes mellitus, n (%) 193 (18) 40 (21) 39 (18) 29 (13) 38 (18) 47 (23) .61
Hypertension, n (%) 710 (67) 117 (60) 136 (64) 151 (67) 151 (70) 155 (76) <.001
Systolic blood pressure,
mmHg, mean ± SD
133 (21) 134 (20) 132 (20) 134 (21) 131 (22) 132 (22) .38
Diastolic blood pressure,
mmHg, mean ± SD
67 (10) 68 (10) 68 (10) 68 (11) 66 (10) 65 (11) .001
Frailty, n (%)
a 107 (10) 14 (7) 13 (6) 28 (13) 12 (6) 40 (20) <.001
Low-density lipoprotein
cholesterol, mg/dL
101 (32) 105 (33) 106 (30) 100 (32) 101 (31) 95 (31) <.001
High-density lipoprotein
cholesterol, mg/dL
55 (16) 60 (16) 57 (15) 54 (14) 54 (16) 49 (15) <.001
C-reactive protein, mg/L,
median (interquartile range)
b
1.96
(0.96–4.59)
1.36
(0.79–3.09)
1.81
(0.85–4.03)
1.79
(0.89–4.71)
2.26
(1.02–5.09)
2.99
(1.41–7.38)
<.001
Cystatin C, mg/L, mean ± SD 1.19 (0.45) 0.79 (0.07) 0.95 (0.04) 1.09 (0.04) 1.26 (0.07) 1.84 (0.62) <.001
Creatinine, mg/dL, mean ± SD 1.09 (0.53) 0.82 (0.16) 0.88 (0.17) 0.98 (0.19) 1.13 (0.23) 1.66 (0.92) <.001
Chronic kidney disease
epidemiology
collaboration eGFR, mL/min
per 1.73 m
2, mean ± SD
59 (17) 74 (11) 68 (12) 61 (12) 53 (12) 38 (13) <.001
Cystatin C eGFR, mL/min per
1.73 m
2, mean ± SD
70 (22) 102 (13) 82 (4) 70 (3) 58 (4) 40 (9) <.001
a Frailty deﬁned as 3 of unintentional weight loss, weakness, exhaustion, and walking slowness.
b Kruskal–Wallis test.
SD = standard deviation.
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2) in those aged 65 and older.
5 Similar ﬁndings
were reported in a community-based cohort, in which
those aged 75 and older with eGFRCR between 45 and
59 mL/min per 1.73 m
2 did not have a greater relative risk
of death than those with eGFR of 60 mL/min per 1.73 m
2
or greater.
6 In an analysis of a representative sample of
adults aged 75 and older drawn from primary care prac-
tices across Britain, eGFRCR less than 45 mL/min per
1.73 m
2 was an independent predictor of mortality com-
pared with the reference group (eGFRCR  60 mL/min
per 1.73 m
2), especially in the ﬁrst 2 years of follow-up,
and there was greater risk of CVD mortality in those with
eGFRCR of 45 to 59 mL/min per 1.73 m
2.
7 In octogenari-
ans in Japan, CKD deﬁned as eGFRCR less than 60 mL/
min per 1.73 m
2 was associated with greater CVD mortal-
ity but not all-cause mortality compared with eGFR
greater than 60 mL/min per 1.73 m
2.
8 These studies are
all partially limited by lack of consideration of the appro-
priate reference group for eGFRCR given that eGFRCR
greater than 60 mL/min per 1.73 m
2 includes some indi-
viduals at low risk (eGFRCR 60–75 mL/min per 1.73 m
2)
and others at higher mortality risk (eGFRCR >75 mL/min
per 1.73 m
2). Furthermore, except for the Japanese study,
there was not a focus on octogenarians, and none evalu-
ated the importance of cystatin C.
When kidney function was assessed using eGFRCR,
the lowest and highest quintiles were associated with
greater mortality than in the lowest-risk group (second-
highest quintile). The association between high eGFRCR
or low serum creatinine and mortality has been noted
previously in the CHS,
22 although the U-shape appears to
be more prominent in octogenarians, as noted in the cur-
rent study. This is probably not because higher eGFR is
a risk factor for death but because higher eGFR partly
reﬂects those with lower muscle mass and malnutrition,
who are thus more likely to die.
24 The inability to distin-
guish whether low creatinine primarily reﬂects low mus-
cle mass (a proxy of frailty) rather than very high GFR
remains a limitation of eGFRCR in elderly adults. The
ﬁnding that only those with eGFRCR below 44 mL/min
per 1.73 m
2 were at greater risk of mortality is consistent
with several of the studies noted above
5–8 and suggests
that, in octogenarians, the threshold at which kidney
function becomes a risk factor may be lower than in
younger individuals. The lower relative risk for death
attributable to impaired kidney function in octogenarians
may reﬂect the higher prevalence of other comorbid con-
ditions, which may lessen the potential for a single condi-
tion such as low GFR to affect mortality. The relative
risk of two conditions translates into a high absolute risk
of mortality given the high mortality in this population.
The results were unchanged despite adjusting for frailty,
although the prevalence of frailty may have been underes-
timated which may have limited the ability to adjust for
it in this cohort.
When eGFRCYS was used to estimate kidney function,
only those in the lowest quintile had greater risk of mor-
tality in adjusted analyses. This is in contrast to prior stud-
ies, including earlier analyses from CHS that studied
younger cohorts, in which the gradient of risk was more
linear.
12–14,22 The reason for these discrepancies is unclear,
but possibilities include differences in the relationship
between kidney function and mortality in octogenarians,
fewer events and therefore less statistical power in the
current analysis, variation in the importance of non-GFR
Figure 1. All-cause mortality according to quintile of kidney
function measure. eGFR = estimated glomerular ﬁltration rate
(mL/min per 1.73 m
2).
Figure 2. Spline evaluating relationship between kidney func-
tion measures and all-cause mortality adjusting for age, sex,
and race and excluding the top and bottom 2.5%. CKD-EPI =
Chronic Kidney Disease Epidemiology Collaboration; eGFR =
estimated glomerular ﬁltration rate (mL/min per 1.73 m
2).
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importantly survivor bias.
Previous studies have demonstrated that cystatin C is
superior to serum creatinine or creatinine-based estimating
equations for prediction of CVD events, including CVD
mortality.
13,25 In the present study, the lowest subgroup of
eGFRCYS had greater risk of CVD mortality than the refer-
ence group, whereas eGFRCR quintiles had no statistically
signiﬁcant association with CVD mortality. These relation-
ships are mostly consistent with the all-cause mortality
data but are partly limited by insufﬁcient statistical power.
The current study has several strengths. CHS All Stars
is one of the largest, best-characterized cohorts of octoge-
narians, with detailed ascertainment of covariates and
CVD risk factors. The CKD-EPI equation, which is
thought to be more accurate than the MDRD equation at
higher levels of GFR, in women, and in white people, was
used to assess kidney function. In addition, this is one of
the few studies in which cystatin C was measured, which
is relevant because cystatin C is now being considered as
an alternative marker of GFR, particular in elderly adults.
Finally, thresholds where risk may increase, including
appropriate reference groups, were evaluated using
eGFRCR and eGFRCYS.
There are some limitations to this study. Participants
who lacked laboratory data were in general less healthy,
so generalizability may be partly limited. Indirect estimates
of GFR that have not been validated in octogenarians were
used. It was not possible to adjust for proteinuria because
urine protein was not measured in this cohort. There was
Table 2. Association Between Kidney Function Measures and All-Cause Mortality
Kidney Function Measure,
mL/min per 1.73 m
2
Mortality per
100 Person-Years
Unadjusted Adjusted
a Adjusted
b
Hazard Ratio (95% Conﬁdence Interval)
Chronic Kidney Disease Epidemiology eGFR quintile
>75 6.9 2.32 (1.28–4.20) 2.40 (1.32–4.37) 2.49 (1.36–4.55)
64–75 3.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
55–63 4.1 1.25 (0.64–2.43) 1.22 (0.63–2.38) 1.23 (0.63–2.41)
44–54 6.4 1.99 (1.09–3.66) 1.84 (1.00–3.38) 1.68 (0.91–3.09)
 43 9.0 2.86 (1.60–5.09) 2.71 (1.52–4.83) 2.28 (1.26–4.10)
Cystatin C eGFR quintile
>88 3.4 1.00 (reference) 1.00 (reference) 1.00 (reference)
75–88 4.9 1.49 (0.80–2.80) 1.45 (0.77–2.72) 1.43 (0.76–2.70)
65–74 4.8 1.43 (0.76–2.67) 1.26 (0.67–2.38) 1.14 (0.60–2.15)
52–64 5.5 1.54 (0.82–2.86) 1.39 (0.74–2.59) 1.21 (0.64–2.27)
<52 11.1 3.33 (1.89–5.87) 2.69 (1.52–4.77) 2.04 (1.12–3.71)
a Adjusted for age, sex, and race.
b Additionally adjusted for hypertension, diabetes mellitus, smoking, body mass index, prevalent cardiovascular disease, prevalent heart failure, low- and
high-density lipoprotein cholesterol, and C-reactive protein.
eGFR = estimated glomerular ﬁltration rate.
Table 3. Association Between Kidney Function Measures and Cardiovascular Mortality
Kidney Function Measure,
mL/min per 1.73 m
2
Mortality per
100 Person-Years
Unadjusted Adjusted
a Adjusted
b
Hazard Ratio (95% Conﬁdence Interval)
Chronic Kidney Disease Epidemiology Collaboration eGFR quintile
75 2.6 1.56 (0.67–3.65) 1.51 (0.64–3.55) 1.48 (0.62–3.51)
64–75 1.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
55–63 2.2 1.29 (0.53–3.10) 1.28 (0.53–3.08) 1.19 (0.49–2.90)
44–54 2.1 1.18 (0.48–2.90) 1.10 (0.45–2.70) 0.95 (0.38–2.35)
 43 4.7 2.73 (1.26–5.93) 2.62 (1.21–5.70) 1.98 (0.90–4.37)
eGFR Cystatin C quintile
75 1.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
65–74 2.1 1.14 (0.69–1.87) 1.02 (0.62–1.69) 0.93 (0.56–1.54)
52–64 2.4 1.23 (0.75–2.01) 1.13 (0.69–1.84) 0.98 (0.60–1.62)
<52 5.6 2.66 (1.75–4.04) 2.18 (1.43–3.33) 1.66 (1.06–2.60)
a Adjusted for age, sex, and race.
b Additionally adjusted for hypertension, diabetes mellitus, smoking, body mass index, prevalent cardiovascular disease, prevalent heart failure, low- and
high-density lipoprotein cholesterol, and C-reactive protein.
eGFR = estimated glomerular ﬁltration rate.
1206 SHASTRI ET AL. JULY 2012–VOL. 60, NO. 7 JAGSlimited statistical power to assess the association between
impaired kidney function and CVD mortality and to
appreciate an association with mortality in the group with
eGFRCR of 45 to 60 mL/min per 1.73 m
2. Factors other
than GFR may inﬂuence cystatin C; despite adjustment
for these variables, residual confounding may have
remained.
26,27 Finally, at the present time cystatin C assays
traceable to an accepted reference are not available, unlike
the isotope dilution mass spectrometry creatinine reference
standard.
In conclusion, even in this oldest subgroup of the popu-
lation, impaired kidney function is associated with all-cause
and CVD mortality, although the risk appears to be greater
only in those with moderately impaired kidney function,
below the current deﬁnition of CKD. Furthermore, this rela-
tionship was U-shaped for eGFRCR, whereas for eGFRCYS,
the risk was primarily present in the lowest quintile. Future
studies that explore novel therapeutic approaches to reduce
CVD and mortality in individuals with imparired kidney
function are needed in the oldest old.
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